Skip to main content
GENFLOW BIOSCIENCES PLC logo

GENFLOW BIOSCIENCES PLC — Investor Relations & Filings

Ticker · GENF ISIN · GB00BP2C3V08 LEI · 213800HVOFXRXVEGDN62 IL Professional, scientific and technical activities
Open in API
Filings indexed 142 across all filing types
Latest filing 2025-10-02 Director's Dealing
Country GB United Kingdom
Listing IL GENF

About GENFLOW BIOSCIENCES PLC

https://genflowbio.com/

Genflow Biosciences PLC is a biotechnology company developing gene therapies that target the aging process. The company's primary mission is to slow or halt aging and reduce the incidence of age-related diseases in both humans and dogs, thereby extending healthspan. Its lead therapeutic candidate, GF-1002, is a gene therapy that delivers a centenarian variant of the Sirtuin 6 (SIRT6) gene. This specific gene variant has been identified in individuals who live to 100 years or more and has demonstrated promising results in pre-clinical studies.

Recent filings

Filing Released Lang Actions
Issue of Equity
Director's Dealing Classification · 100% confidence The document is an RNS announcement from Genflow Biosciences PLC regarding a capital raise through the subscription of new ordinary shares and the issuance of warrants. It also includes a mandatory PDMR (Person Discharging Managerial Responsibilities) notification regarding the CEO's transaction. While it contains elements of director dealings (DIRS), the primary purpose of the announcement is the capital raise (share issuance and financing), which falls under the 'Share Issue/Capital Change' category. The document is a direct announcement of these corporate actions rather than a report publication announcement.
2025-10-02 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF YEAR RESULTS' for Genflow Biosciences PLC for the period ended 30 June 2025. It contains comprehensive financial statements, including the Consolidated Statement of Financial Position, Statement of Comprehensive Income, Statement of Cash Flows, and Statement of Changes in Equity. Although it is distributed via an RNS (Regulatory News Service) header, it is not merely an announcement of a report; it contains the full substantive financial data and management commentary for the interim period, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership (acquisition of voting rights) by an individual (Jonathan Mark Swann) in Genflow Biosciences PLC, crossing a specific threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-09-19 English
Genflow Strengthens IP Portfolio
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Reach) service. It announces a specific corporate development: the filing of a patent examination request in China for the company's SIRT6 variants. As this is a general corporate announcement regarding business operations and intellectual property that does not fit into specific categories like financial results, dividends, or board changes, it is classified as a general regulatory filing/announcement.
2025-09-19 English
Genflow Signs CDAs with Animal Health Companies
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service) platform. It announces that Genflow Biosciences PLC has signed Confidential Disclosure Agreements (CDAs) with animal health companies. This is a corporate announcement regarding business development and strategic partnerships, which does not fall into specific categories like financial reports, dividends, or M&A. Therefore, it is classified as a general regulatory announcement.
2025-09-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details an acquisition of voting rights by a shareholder (Jonathan Mark Swann) in Genflow Biosciences PLC, crossing a specific threshold (from 6.01% to 7.01%). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-08-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.